Core Viewpoint - 基石药业's RET inhibitor, Pralsetinib (普吉华®), has been included in the latest National Medical Insurance Drug List in China, effective January 1, 2026, which is expected to enhance its market penetration and sales growth [1] Group 1: Company Developments - 基石药业's stock rose by 5.57% to HKD 6.07, with a trading volume of HKD 22.7042 million [1] - The company has successfully advanced four innovative drugs to market approval, with three of them having completed clinical trials and registration in China, now included in the national medical insurance list [1] Group 2: Market Expectations - Tianfeng Securities reported in August that the inclusion of Pralsetinib in the insurance list is anticipated to accelerate its market uptake [1] - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] Group 3: Technological Advancements - 基石药业 has developed an innovative internal ADC technology platform, characterized by optimized proprietary linkers to improve tumor-selective payload release [1] - The platform supports multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for the company's future growth [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 3.733 billion yuan for Q3 2025, representing a year-on-year increase of 47.35%, with a net profit of 1.616 billion yuan, up 52.01% year-on-year [5] - The sales revenue of the drug Vomeletin is steadily increasing, enhancing patient accessibility and expanding the beneficiary population of lung cancer patients [8] - The company is expected to see revenue growth of 27.0%, 19.0%, and 13.7% for the years 2025, 2026, and 2027, respectively, with net profits of 1.593 billion yuan, 1.901 billion yuan, and 2.169 billion yuan for the same years [10] Financial Performance - For the first three quarters of 2025, the overall gross margin was 96.79%, an increase of 1.03 percentage points year-on-year, with an operating cash flow net amount of 1.730 billion yuan, up 39.94% year-on-year [7] - The company’s revenue for 2025 is projected to be 4.520 billion yuan, with a year-on-year growth of 27.0% [13] - The expected earnings per share (EPS) for 2025 is 3.54 yuan, with a price-to-earnings (P/E) ratio of 31.08 [13] Product Development and Market Strategy - The company has established a specialized team for rare target marketing, leveraging the clinical advantages of its products to enhance academic promotion and marketing strategies [9] - The drug Vomeletin has been recommended in the latest expert consensus for the treatment of advanced NSCLC with EGFR PACC mutations, further enhancing its clinical value [6][8] - The RET inhibitor product, Pujihua, is expected to enter the national medical insurance directory, improving drug accessibility for patients [10]